FIT Biotech Oy’s Board of Directors has decided on the directed share issue without payment to the Company itself


FIT Biotech Oy
Company release November 30, 2017 at 4 pm

FIT Biotech Oy’s Board of Directors has decided on the directed share issue without payment to the Company itself

This has been published on November 21, 2017 as a press release

FIT Biotech Oy’s (Company) Board of Directors has resolved November 21, 2017 to issue 50,000,000 K-shares without payment to the Company itself based on the authorization granted by the General meeting on September 15, 2016. The purpose is to use the shares to further implement current Bracknor funding programme.

FIT BIOTECH OY
Board of Directors

For further information:
Chairman of the Board of Directors Rabbe Slätis
Tel: +358 40 840 6749
E-mail: rabbe.slatis@fitbiotech.com

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media